Sutro Biopharma STRO 深 滬
已收盤 10-16 16:00:00 美东时间
10.94
-0.520
-4.54%
華盛通- 最 高11.47
- 今 開11.47
- 成交量 36.35万股
- 最 低 10.585
- 昨 收 11.46
- 總市值 1.81亿
- 52周最高 43.85
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.211
- 委 比 37.46%
- 總股本 1658.12万
- 歷史最高 283.00
- 量 比 0.97
- 振 幅 7.72%
- 歷史最低 5.231
- 每 手 1
- 風險率 8.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sutro Biopharma收跌4.54%，成交额401.76万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:47
PCVX收跌2.53%，成交额2.06亿美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 04:54
美股大行评级 | 潜在涨幅279.75%！Jones Trading维持Contineum Therapeutics(CTNM)"买入"评级，目标价上调至30美元
今日重点评级关注：Jones Trading：维持Contineum Therapeutics"买入"评级，目标价从24美元升至30美元；StoneX：维持Forum Markets"投机性买入"评级，目标价从9美元升至12美元
10-16 12:30
Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.
10-15 21:12
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Sutro Biopharma, a clinical-stage oncology company, announced its participation in the 17th Annual World ADC Conference in San Diego, October 12-15, 2026. The company highlighted progress in its pipeline, including presentations on STRO-004, STRO-006, and STRO-227, showcasing safety, efficacy, and overcoming resistance in ADCs. Sutro aims to deliver next-generation ADCs with improved therapeutic profiles.
10-12 12:00
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Vaxcyte, Inc. announced the pricing of concurrent public offerings totaling approximately $1 billion, including shares of common stock, pre-funded warrants, and convertible senior notes. The company plans to use the proceeds for clinical development of its VAX-31 and VAX-24 vaccine candidates, manufacturing scale-up, commercial preparations, and other research and development activities. The offerings are expected to close on October 9, 2026, sub...
10-07 02:48
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Vaxcyte appoints Luis Jodar, Ph.D., as Chief Medical Officer and David McAvoy, J.D., as Chief Legal Officer. Jodar brings over 30 years of experience in vaccine development, including leadership at Pfizer, while McAvoy has three decades of legal leadership in the biopharmaceutical industry. The company also updated its timeline for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expected by the end of October 2026.
09-03 20:05
Vaxcyte to Participate in Upcoming Investor Conferences
Vaxcyte, Inc. announced that its management will participate in fireside chats and host one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference (September 8-10, 2026) and the Cantor Global Healthcare Conference (September 9-11, 2026). The fireside chats will be webcast live and available for 30 days post-conference. Vaxcyte is a vaccine innovation company developing high-fidelity vaccines, including VAX-31 and VAX-24, which aim t...
08-27 20:05
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
